VKTX NASDAQ
Credit Risk of going bust: lower than 84% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Viking Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.1M against a stock market value of $3.08B.
Distance to default 10.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.0M (short-term plus half of long-term), stock volatility 66.2%; Altman Z'' -5.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92121
US
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRÃ). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRÃ agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kelly-Gemmell Doroth | A-Award | 6,333 | — | 2026-08-01 |
| Kelly-Gemmell Doroth | A-Award | 40,800 | $31.74 | 2026-08-01 |
| Kelly-Gemmell Doroth | 0 | — | 2026-08-01 | |
| Lian Brian | S-Sale | 148,517 | $33.32 | 2026-07-29 |
| ZANTE GREG | S-Sale | 21,217 | $33.47 | 2026-07-29 |